How to Handle Co-authorship When Not Everyone's Research Contributions Make It into the Paper.

Authorship Authorship criteria Ethics Negative results Substantial contribution

Journal

Science and engineering ethics
ISSN: 1471-5546
Titre abrégé: Sci Eng Ethics
Pays: England
ID NLM: 9516228

Informations de publication

Date de publication:
12 04 2021
Historique:
received: 02 10 2020
accepted: 24 03 2021
entrez: 12 4 2021
pubmed: 13 4 2021
medline: 19 8 2021
Statut: epublish

Résumé

While much of the scholarly work on ethics relating to academic authorship examines the fair distribution of authorship credit, none has yet examined situations where a researcher contributes significantly to the project, but whose contributions do not make it into the final manuscript. Such a scenario is commonplace in collaborative research settings in many disciplines and may occur for a number of reasons, such as excluding research in order to provide the paper with a clearer focus, tell a particular story, or exclude negative results that do not fit the hypothesis. Our concern in this paper is less about the reasons for including or excluding data from a paper and more about distributing credit in this type of scenario. In particular, we argue that the notion 'substantial contribution', which is part of the International Committee of Medical Journal Editors (ICMJE) authorship criteria, is ambiguous and that we should ask whether it concerns what ends up in the paper or what is a substantial contribution to the research process leading up to the paper. We then argue, based on the principles of fairness, due credit, and ensuring transparency and accountability in research, that the latter interpretation is more plausible from a research ethics point of view. We conclude that the ICMJE and other organizations interested in authorship and publication ethics should consider including guidance on authorship attribution in situations where researchers contribute significantly to the research process leading up to a specific paper, but where their contribution is finally omitted.

Identifiants

pubmed: 33844100
doi: 10.1007/s11948-021-00303-y
pii: 10.1007/s11948-021-00303-y
pmc: PMC8041690
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

27

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States

Références

Sci Eng Ethics. 2020 Aug;26(4):1967-1993
pubmed: 31161378
Sci Adv. 2017 Nov 08;3(11):e1700404
pubmed: 29152564
JAMA. 1990 Mar 9;263(10):1405-8
pubmed: 2304220
BMC Med Ethics. 2014 May 28;15:42
pubmed: 24885855
Dev World Bioeth. 2013 Dec;13(3):149-57
pubmed: 22994914
Sci Eng Ethics. 2020 Apr;26(2):1031-1037
pubmed: 31912431
J Clin Epidemiol. 2017 Aug;88:92-101
pubmed: 28603008
BMJ Open. 2016 Feb 17;6(2):e008681
pubmed: 26888726
Am J Gastroenterol. 2008 Sep;103(9):2181-3
pubmed: 18671812
Med Health Care Philos. 2015 May;18(2):171-5
pubmed: 25034787
Am J Health Behav. 2005 Nov-Dec;29(6):579-87
pubmed: 16336112
Sci Eng Ethics. 2015 Oct;21(5):1315-29
pubmed: 25348894
JAMA. 1990 Mar 9;263(10):1392-5
pubmed: 2406473
J Med Ethics. 2019 May;45(5):331-338
pubmed: 30824494
J Cereb Blood Flow Metab. 2010 Jul;30(7):1263-4
pubmed: 20596038
BMJ. 2011 Oct 25;343:d6128
pubmed: 22028479
Account Res. 2018;25(4):199-211
pubmed: 29400074
Account Res. 2017;24(4):243-267
pubmed: 28128975
PLoS One. 2008 Aug 28;3(8):e3081
pubmed: 18769481
BMC Med Ethics. 2014 Jul 02;15:53
pubmed: 24989359
Sci Eng Ethics. 2012 Jun;18(2):199-212
pubmed: 21312000
Health Technol Assess. 2000;4(10):1-115
pubmed: 10932019
PLoS One. 2011;6(9):e23477
pubmed: 21931600

Auteurs

Gert Helgesson (G)

Stockholm Centre for Healthcare Ethics (CHE), Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden. gert.helgesson@ki.se.

Zubin Master (Z)

Biomedical Ethics Research Program and Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA.

William Bülow (W)

Department of Philosophy, Stockholm University, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH